MediWound Ltd. (NASDAQ:MDWD) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET

Company Participants

Monique Kosse - MD, LifeSci Advisors

Ofer Gonen - CEO

Boaz Gur-Lavie - CFO

Conference Call Participants

Josh Jennings - Cowen

Francois Brisebois - Oppenheimer

Swayampakula Ramakanth - H.C. Wainwright

Operator

Good day, and welcome to the MediWound's Third Quarter 2022 Earnings Call. Today's conference call is being recorded.

And at this time, I would like to turn the conference over to Monique Kosse of LifeSci Advisors. Please go ahead, ma'am.

Monique Kosse

Thank you, operator, and welcome, everyone.

Earlier today, MediWound issued a press release announcing financial results for the third quarter ended September 30, 2022. You may access that release on the company's website under the Investors tab.

With us today are Ofer Gonen, Chief Executive Officer of MediWound; and Boaz Gur-Lavie, Chief Financial Officer. Following our prepared remarks, we will open the call for Q&A.

Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session relating to MediWound's expected future performance, future business prospects or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995.

Although, the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties and could differ materially from those forecast due to the impact of many factors beyond the control of MediWound.

The company assumes no obligation to update or supplement any forward-looking statements, whether as a result of new information, future events or otherwise. Participants are directed to cautionary notes set forth in today's press release as well as Risk Factors set forth in MediWound's Annual Report filed with the SEC for factors that could cause actual results to differ materially from those anticipated in the forward-looking statements.

The conference call is the property of MediWound, and any recording or rebroadcast is expressly prohibited without the written consent of MediWound.

Now, I would like to turn the call over to Ofer Gonen, Chief Executive Officer of MediWound. Ofer?

Ofer Gonen

Thank you, Monique. Good morning, everyone. Welcome to our third quarter 2022 conference call to discuss our financial and operational highlights.

This quarter, we continue to be on track with a series of positive announcements across all our programs. We are approaching several significant inflection points for the company. We believe that once NexoBrid is approved, it will generate meaningful revenues in 2023 and significant growth going forward. Following the launch of NexoBrid, we will focus on $1 billion market opportunity presented to us with EscharEx where we plan to initiate a Phase 3 study next year.